Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.
Syncell Inc.
SYNCELL’s Microscoop spatial proteomics technology can turn a microscope into a “Microscoop” – the world’s first in-cell “pickable” microscope that applies an AI algorithm to selectively recover proteins and nucleic acids from a specified subcellular location. SYNCELL is excited to provide researchers its novel tool to advance the field of proteomics and play a role in solving some of the world’s most complex biology and disease problems.
Streck
Established in 1971, Streck develops quality control and sample stabilization products that help clinical and research laboratories worldwide feel confident in the validity of their results. Streck products are manufactured in La Vista, Nebraska and shipped worldwide.
Stellaromics
Stellaromics is dedicated to pioneering breakthroughs in 3D spatial multi-omics. The company’s mission is to empower researchers with cutting-edge tools that illuminate the complexities of biological systems, enabling groundbreaking discoveries that improve human health.
Standard BioTools
Standard BioTools™, previously known as Fluidigm, is driven by a bold vision Unleashing tools to accelerate breakthroughs in human health. Standard BioTools provides an established portfolio of essential, standardized next-generation technologies with CyTOF® and microfluidics capabilities to the cancer community. The company empowers biomedical researchers to interrogate immune cell function and the tumor microenvironment with unprecedented resolution for reliable and repeatable insights they can trust. Together we will transform the future of cancer care.
SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.
SomaLogic (an Illumina company)
SomaLogic™, an Illumina company, is the only high-plex proteomics technology on the market that scales with precision. It provides the largest number of protein measurements and the greatest number of orthogonally confirmed protein reagents in the proteomics industry – 11,000 protein measurements simultaneously from sample volumes as low as 55 µl. This gives researchers access to half of the human proteome in just one assay. Over a decade of proof in major cardiometabolic, neurology and oncology studies using the SomaScan Platform, sponsored by leading pharma companies with more than 1,200 publications to date, have driven efforts to significantly accelerate trials.
Singular Genomics
Singular Genomics is driving innovation at the forefront of multiomics. Dedicated to supporting the scientific community, we focus on creating scientific advancements influenced by real-world feedback and solution-oriented development. As a publicly-traded life science technology company, we specialize in advanced next-generation sequencing (NGS) and multiomic technologies, developing products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is an innovative benchtop sequencer featuring a novel 4-color rapid sequencing-by-synthesis (SBS) chemistry and advanced engineering, providing single-day turnaround times for various applications. Our recently launched G4X Spatial Sequencer, which is an upgrade to the G4 Sequencing Platform, is designed to offer high throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
Signios Bio
Signios Biosciences, (formerly named MedGenome US Research) is a multiomics and bioinformatics company dedicated to revealing the intricate signals within biological data. By combining cutting-edge AI, multiomic technologies, and scientific partnership, Signios Bio enables the discovery and development of next-generation therapies and diagnostics that are more inclusive, effective, and transformative.
Signal Bioscience
Signal Bioscience is a life science tools company developing novel Processor-Mediated PCR (pmPCR) chemistries that dramatically expand the multiplexing, sensitivity, and speed of existing qPCR and dPCR instruments. Our platform enables up to 25-plex in qPCR and 100-plex in digital PCR — without new hardware — by precisely controlling signal intensity and timing within a single fluorescence channel. We are developing high-impact applications in oncology, including multiplex KRAS mutation detection, HPV-associated cancer monitoring, and minimal residual disease (MRD) liquid biopsy assays.